Healthcare entity
All 1 tracked stories fall under one category: market-trends. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 4.1 for the broader beat in this window.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 4.1 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6. LOTTE Biologics appears in 1 tracked Healthcare story from March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering LOTTE Biologics. Shared-story counts are live from our verified record — not editorial picks.
DCAT Week 2026
LOTTE Biologics engages in high-level partnership talks in New York City.
ADC Expansion
Completion of specialized ADC manufacturing lines at the Syracuse facility.
Songdo Groundbreaking
Construction begins on the first Mega Plant in Songdo, South Korea.
Syracuse Acquisition
LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Source: singaporestar.com · cambodiantimes.com
LOTTE Biologics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
